mesofiller®

PIGMENT CONTROL PROFESSIONAL SOLUTIONS

dark spots, trust the leader

Professional depigmenting method that removes skin spots and prevents their reappearance for a short-and long-term outcome.

Manifestations of aging

The passage of time results in the appearance of expression lines that gradually transform into deeper wrinkles around the eyes, the mouth, between the eyebrows, the corners of the mouth or in the nasolabial folds. The skin tissue loses elasticity, its texture changes (thickening or becoming thinner) and superficial abnormalities appear (small blood vessels in the skin, dark spots). Age also reveals other problems that affect the aesthetic harmony of the face, such as the loss of volume in lips and cheeks.

If aging cannot be avoided, it can be slowed with medical procedures that are minimally invasive and achieve immediate and lasting results. The facial fillers of hyaluronic acid are one of these.

densiMatrix® technology

  • > High degree of modification
  • Homogeneous cross-linking process, without free HA.
  • > Strict standardisation
  • Control of key parameters in order to ensure product quality.
  • > Maximum safety
  • Unique purification process that ensures minimal residual value of BDDE < 0.05 ppm among the lowest BDDE values on the market.
  • > Very low swelling factor.
  • That ensures a predictable value after insertion as well as a lower risk of edema production.

Durability, safety and improvement of tissue quality

  • > High adaptation and integration in the tissues
  • Full integration that stimulates regeneration pathways, improving tissue quality.
  • > Durability from 9 to 12 months
  • Control of key parameters to ensure product quality
  • > Stimulation of the tissue repair mechanism
  • > Complete biocompatibility

  • Day 0: after implantation, full adaptation of the filler can be seen in the dermis.

  • After 6 months: high integration and durability of the gel are seen.

  • After 9-12 months: the presence of filler continues, together with the formation of new conjunctive tissue with no nodules or visible residual anechoic areas.

    Over 12 months no presence of nodules is seen (anechoic areas).